HLP004 Achieves Clinically Meaningful Efficacy in Phase 2 GAD Study, Showing 10.4-Point HAM-A Reduction
HELP sits 46% above its 52-week low of $4.81.
Summary
Helus Pharma, operating as Cybin Inc., announced positive topline results from its Phase 2 signal detection study for HLP004 in patients with moderate-to-severe generalized anxiety disorder (GAD). The study demonstrated clinically meaningful efficacy, with the 20mg dose achieving a mean 10.4-point reduction in the HAM-A scale from baseline at six weeks (p<0.0001) and showing 67% responders at six months. The drug was also well-tolerated with no drug-related serious adverse events. These strong results for a difficult-to-treat patient population represent a significant de-risking event for the clinical-stage pharmaceutical company and provide a strong catalyst for continued development. Investors will now watch for progression to later-stage trials and further regulatory updates.
At the time of this announcement, HELP was trading at $7.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $4.81 to $9.83. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.